Drug Type Bispecific antibody |
Synonyms BNT327, PM 8002, PM8002 |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Extensive stage Small Cell Lung Cancer | Phase 3 | United States | 03 Feb 2025 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | Australia | 03 Feb 2025 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | United Kingdom | 03 Feb 2025 | |
Non-Small Cell Lung Cancer | Phase 3 | United States | 07 Jan 2025 | |
Non-Small Cell Lung Cancer | Phase 3 | Australia | 07 Jan 2025 | |
Non-Small Cell Lung Cancer | Phase 3 | Turkey | 07 Jan 2025 | |
Non-Small Cell Lung Cancer | Phase 3 | United Kingdom | 07 Jan 2025 | |
Triple Negative Breast Cancer | Phase 3 | China | 11 Jun 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 26 Jun 2023 | |
Metastatic Colorectal Carcinoma | Phase 2 | China | 26 May 2025 |
NCT05438329 (AACR2025) Manual | Phase 1/2 | 8 | mnykbucfys(lzidwatxqi) = Stomatitis was reported in 6/8 patients (Grade 3 in 2 patients), which led to a dose reduction of BNT325 in 3 patients arnwbncwrc (sjhhguqivo ) View more | Positive | 27 Apr 2025 | ||
Phase 2 | Extensive stage Small Cell Lung Cancer First line | 50 | BNT327 30 mg/kg + Platinum-Etoposide | yyufbnwsze(resuopplaf) = fdalevmhhr zpaullcdyq (pxcckjuhmt ) View more | Positive | 26 Mar 2025 | |
Phase 2 | 70 | BNT327 + Paclitaxel | usekdcwvgk(jybtbeheda) = czopsidfxl uqkgcsdlxi (erytqpkvdz, 29.4 - 54.4) View more | Positive | 26 Mar 2025 | ||
NCT05918133 (SABCS2024) Manual | Phase 1/2 | Triple Negative Breast Cancer First line | 42 | oixtrobbmm(boyhlbpncf) = skyhgnktlz dakfbljzwn (hhjdrzvdpb ) View more | Positive | 10 Dec 2024 | |
Phase 1/2 | 42 | asgiepajmq(famwgztnsg) = vkwhmczrio vwamwyjgeh (mgsvizeboi, 63.2 - 89.7) View more | Positive | 16 Sep 2024 | |||
NCT05918445 (ESMO2024) Manual | Phase 1/2 | Advanced Renal Cell Carcinoma Second line | 53 | PM8002/BNT-327 | ystcxvecfu(xwtfyjkrmm) = jievtwtxeo lrhykzhegi (ibrqhiirmv ) View more | Positive | 15 Sep 2024 |
Phase 2 | 64 | lfodqfgbon(birksifxwa) = lqxnwjcrjp hugxwowfkp (ppsxxshghf, 41.8 - 67.2) View more | Positive | 14 Sep 2024 | |||
(PD-L1 TPS<1%) | lfodqfgbon(birksifxwa) = lzdzdmyugi hugxwowfkp (ppsxxshghf, 18.6 - 55.9) View more | ||||||
NCT05918445 (ASCO2024) Manual | Phase 1/2 | 87 | miunqgblbx(udlrjdonio) = fyggjelcte vqyowzpvcq (ztlkdbmopz ) View more | Positive | 24 May 2024 | ||
(PROC) | miunqgblbx(udlrjdonio) = xamczzvmoe vqyowzpvcq (ztlkdbmopz ) View more | ||||||
NCT05918445 (ASCO2024) Manual | Phase 1/2 | 61 | ysowsaqoir(ubhlksbeti) = slpjznonxm utoeswjdae (euhblrlzef ) View more | Positive | 24 May 2024 | ||
(Treatment-naive) | ysowsaqoir(ubhlksbeti) = pbeskspdod utoeswjdae (euhblrlzef ) View more | ||||||
Phase 2 | Small Cell Lung Cancer Second line | 26 | ptcasifdcn(ngzganisoi) = ncflrxsgxc yyllfeevsv (ogjlxlnvpq ) View more | Positive | 21 Oct 2023 |